The Serametrix Serum Profiling Assay measures patient serum antibodies against proprietary panels of tumor-specific antigens. Measuring the patient’s baseline and post-treatment anti-tumor immune response is pivotal for successful clinical development of novel cancer therapies. Baseline measurements correlated to clinical outcome may help identify responder patients. Drugs that induce a broad-based immune response in the days and weeks following administration are more likely to meet the clinical end-points required for development and regulatory approval.
The Serametrix Serum Profiling Assay includes study design, serum profiling, and results with comprehensive analysis and interpretation, with expertise to help to define next steps and further studies.
Immunoassays for serum profiling for NY-ESO-1 and other tumor antigens are available for the following cancer types:
To discuss ideas for your study or request a quote, click here.